Trial Profile
A phase I Clinical Trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Tipifarnib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms PMDS17
- 09 Jul 2011 New trial record